When the world gets closer.

We help you see farther.

Sign up to our expressly international daily newsletter.

Already a subscriber? Log in.

You've reach your limit of free articles.

Get unlimited access to Worldcrunch

You can cancel anytime.

SUBSCRIBERS BENEFITS

Ad-free experience NEW

Exclusive international news coverage

Access to Worldcrunch archives

Monthly Access

30-day free trial, then $2.90 per month.

Annual Access BEST VALUE

$19.90 per year, save $14.90 compared to monthly billing.save $14.90.

Subscribe to Worldcrunch
Geopolitics

Why Latin Americans Fear The Chinese Vaccine

People around the world and around Latin America are wary of the vaccination campaigns to fight COVID-19. But there is a particular hesitancy toward the vaccine solution arriving from China that by now should be discarded, along with stereotypes.

A Brazilian woman gets the Chinese-made CoronaVac vaccine.
A Brazilian woman gets the Chinese-made CoronaVac vaccine.
Lucio Tavora/Xinhua via ZUMA
Martin González Solar and Víctor Contreras Kong

-OpEd-

Polls reveal a range of public fears in Latin America about the various COVID-19 vaccines. Yet the one prompting the most concerns are the Chinese vaccine Coronavac, created by the firm Biotech Sinovac.

In a recent poll by Activa Research 51.4% of respondents openly admitted to distrusting that vaccine, with only 24% expressing confidence. The Pfizer BioNTech vaccine had a 40.9% distrust rate and a 31.3% trust rate. Several factors are at play in the negative perceptions of Coronavac. There is for example the circulation of scientific misinformation among the public and a good deal of fake news used to magnify political tensions and fuel incendiary talk between competing states.

This contrast in trust levels between Western and Chinese vaccines may also be questioned considering that the Pfizer BioNTech and Moderna vaccines use mRNA, a new and promising technology that is arguably still in development, while Sinovac uses classic vaccine technology, tried and tested over a century.

Chinese products have had to undertake a lengthy validation process before being accepted as high-quality by health officials in the region and around the world. We should also consider China's notable advances in scientific research, the extremely high level of training given to professionals there and development of first-generation infrastructures for manufacturing sophisticated, innovative, high-tech products. These include a vaccine that has a 78% efficacy rate of avoiding serious illness in case of infection.

Evidently China is no longer worthy of the would-be "cheap"" Made in China label, and can rightly boast that it is the creator of high-quality products across numerous sectors.

While the country defines itself as a communist state, it has become an efficient model of capitalism, the entrepreneurial spirit and of tech startups and enterprises. Biotech Sinovac began that way. It is of little use then to continue to view China as a rickety, old communist state and insist on overlooking its advances in medical, computing and space technologies.

Perhaps to change our view of the Chinese vaccine, we could just ditch our stereotypes.

*The authors are Beijing-based lawyers.

You've reached your limit of free articles.

To read the full story, start your free trial today.

Get unlimited access. Cancel anytime.

Exclusive coverage from the world's top sources, in English for the first time.

Insights from the widest range of perspectives, languages and countries.

Worldcrunch Magazine #37 — Iran And The Taliban: The Drug Connection
Worldcrunch

This is the latest edition of Worldcrunch Magazine, a selection of our best articles of the week from the best international journalists, produced exclusively in English for Worldcrunch readers.

>> DISCOVER IT HERE <<

Keep reading...Show less

You've reached your limit of free articles.

To read the full story, start your free trial today.

Get unlimited access. Cancel anytime.

Exclusive coverage from the world's top sources, in English for the first time.

Insights from the widest range of perspectives, languages and countries.

Already a subscriber? Log in.

You've reach your limit of free articles.

Get unlimited access to Worldcrunch

You can cancel anytime.

SUBSCRIBERS BENEFITS

Ad-free experience NEW

Exclusive international news coverage

Access to Worldcrunch archives

Monthly Access

30-day free trial, then $2.90 per month.

Annual Access BEST VALUE

$19.90 per year, save $14.90 compared to monthly billing.save $14.90.

Subscribe to Worldcrunch

The latest